{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:18:44Z","timestamp":1791119924982,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","award":["00023728"],"award-info":[{"award-number":["00023728"]}],"id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.autrev.2016.07.023","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T22:31:31Z","timestamp":1470177091000},"page":"983-993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study"],"prefix":"10.1016","volume":"15","author":[{"given":"Lucile","family":"Musset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Bentow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ghirardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrike","family":"Schmeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda-De La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Ortiz-Villalvazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bizzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Imbastaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Vencovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Krystufkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Fredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Belmondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Danko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2016.07.023_bb0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/BOR.0b013e328358bd85","article-title":"Myositis autoantibodies","volume":"24","author":"Casciola-Rosen","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","article-title":"Dermatomyositis and polymyositis","volume":"1184","author":"Mammen","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2016.07.023_bb0015","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2016.07.023_bb0020","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3899\/jrheum.120682","article-title":"Classification, diagnosis, and management of idiopathic inflammatory myopathies","volume":"40","author":"Lazarou","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.07.023_bb0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2016.07.023_bb0040","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3899\/jrheum.131069","article-title":"ANCA-associated vasculitis: a prothrombotic state even in remission?","volume":"40","author":"Monach","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-013-0349-8","article-title":"Clinical heterogeneity and outcomes of antisynthetase syndrome","volume":"15","author":"Hervier","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2016.07.023_bb0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semarthrit.2007.06.002","article-title":"Primary Sjogren's syndrome: current and prospective therapies","volume":"37","author":"Thanou-Stavraki","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0055","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2016.07.023_bb0060","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2016.07.023_bb0065","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","author":"Betteridge","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0070","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2016.07.023_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.phrs.2014.03.001","article-title":"Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases","volume":"88","author":"Ulivieri","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2016.07.023_bb0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.autrev.2016.07.023_bb0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2016.07.023_bb0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7326\/0003-4819-159-1-201307020-00022","article-title":"Discontinuation of statins in routine care settings","volume":"159","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000174","article-title":"Muscle-related side-effects of statins: from mechanisms to evidence-based solutions","volume":"26","author":"Taylor","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-203094","article-title":"Persisting weakness after withdrawal of a statin","volume":"2014","author":"Mygland","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.autrev.2016.07.023_bb0115","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","article-title":"Immune-mediated necrotizing myopathies\u2014a heterogeneous group of diseases with specific myopathological features","volume":"38","author":"Stenzel","year":"2012","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0120","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.autrev.2013.07.001","article-title":"Statin-induced necrotizing myositis\u2014a discrete autoimmune entity within the \u201cstatin-induced myopathy spectrum\u201d","volume":"12","author":"Hamann","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2016.07.023_bb0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","article-title":"Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity","volume":"72","author":"Endo","year":"1976","journal-title":"FEBS Lett"},{"key":"10.1016\/j.autrev.2016.07.023_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1432-1033.1977.tb11637.x","article-title":"Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase","volume":"77","author":"Endo","year":"1977","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.autrev.2016.07.023_bb0135","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1008-1050","article-title":"A gift from nature: the birth of the statins","volume":"14","author":"Endo","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","article-title":"Statin therapy and autoimmune disease: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.06.005","article-title":"Statin: new life for an old drug","volume":"88","author":"Bifulco","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2016.07.023_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.CIR.99.2.185","article-title":"Natural statins and stroke risk","volume":"99","author":"Furberg","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2016.07.023_bb0155","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1080\/09593330.2015.1058422","article-title":"Stability and removal of atorvastatin, rosuvastatin and simvastatin from wastewater","volume":"36","author":"Sulaiman","year":"2015","journal-title":"Environ Technol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","article-title":"Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis","volume":"7","author":"Mammen","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbspin.2013.06.008","article-title":"Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins","volume":"81","author":"Lahaye","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2016.07.023_bb0170","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0175","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000124","article-title":"Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology","volume":"2","author":"Alshehri","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2016.07.023_bb0180","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1373\/clinchem.2014.227819","article-title":"A 62-year-old woman with muscle weakness","volume":"61","author":"Dobbels","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.autrev.2016.07.023_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2007.01.017","article-title":"Biomarkers for early detection of breast cancer: what, when, and where?","author":"Levenson","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2016.07.023_bb0190","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0195","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2016.07.023_bb0200","doi-asserted-by":"crossref","first-page":"405956","DOI":"10.1155\/2014\/405956","article-title":"Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies","volume":"2014","author":"Musset","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2016.07.023_bb0205","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2016.07.023_bb0210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0215","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3899\/jrheum.120804","article-title":"Classification and diagnostic investigation in inflammatory myopathies: a study of 99 patients","volume":"40","author":"Danielsson","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0220","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/ar1455","article-title":"Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies","volume":"7","author":"Mahler","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2016.07.023_bb0225","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0230","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1749-6632.2009.05127.x","article-title":"Epitope specificity and significance in systemic autoimmune diseases","volume":"1183","author":"Mahler","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2016.07.023_bb0235","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2548","article-title":"Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies","volume":"10","author":"Mahler","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2016.07.023_bb0240","doi-asserted-by":"crossref","first-page":"315179","DOI":"10.1155\/2014\/315179","article-title":"Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"2014","author":"Mahler","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2016.07.023_bb0245","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3949\/ccjm.81a.13158","article-title":"Identifying statin-associated autoimmune necrotizing myopathy","volume":"81","author":"Albayda","year":"2014","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0250","doi-asserted-by":"crossref","DOI":"10.1007\/s00393-015-0029-3","article-title":"Immune-mediated necrotizing myopathy","author":"Bergua","year":"2016","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cca.2013.05.011","article-title":"Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens","volume":"424","author":"Bentow","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2016.07.023_bb0260","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.07.023_bb0265","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/art.20120","article-title":"The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus","volume":"50","author":"McClain","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000416","article-title":"Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan","volume":"94","author":"Watanabe","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2016.07.023_bb0275","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/ard.44.4.266","article-title":"Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill","volume":"44","author":"Todd","year":"1985","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.07.023_bb0280","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2016.07.023_bb0285","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/kev229","article-title":"Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience","volume":"54","author":"Klein","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2016.07.023_bb0290","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/rheumatology\/kep355","article-title":"Re-classifying myositis","volume":"49","author":"Sultan","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2016.07.023_bb0295","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2016.07.023_bb0300","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.revmed.2013.12.006","article-title":"Autoantibody profile in myositis","volume":"35","author":"Allenbach","year":"2014","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2016.07.023_bb0305","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0310","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0315","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s10067-007-0537-x","article-title":"The development of systemic sclerosis classification criteria","volume":"26","author":"Walker","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0320","first-page":"2055","article-title":"Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse","volume":"23","author":"Amigues","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2016.07.023_bb0325","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0330","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis\u2014a report from the EULAR Scleroderma Trials and Research (EUSTAR) group data base","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.07.023_bb0335","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2016.07.023_bb0340","first-page":"A2539","article-title":"Atorvastatin-induced autoimmune myopathy: an emerging dominant entity in patients with autoimmune myopathy presenting with a pure polymyositis phenotype","volume":"67","author":"Landon-Cardinal","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2016.07.023_bb0345","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2016.07.023_bb0350","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2016.07.023_bb0355","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.nmd.2014.01.002","article-title":"Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients","volume":"24","author":"Wang","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.023_bb9000","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216301689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216301689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T19:51:42Z","timestamp":1656964302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997216301689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1568997216301689"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.07.023","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}